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Abstract: In vitro permeation studies using nail clippings or nail plates are commonly used in the 
development of transungual formulations. However, there are ethical, safety and cost issues 
associated with sourcing such tissues. Herein, we describe a preliminary approach is described for 
the design and manufacture of a human nail model surrogate based on 3D printing. To evaluate 
these 3D printed constructs, nails were mounted in conventional glass Franz cells and a commercial 
antifungal lacquer formulation containing ciclopirox olamine was applied daily to the surrogate 
printed surfaces for a period of 14 days. On days 8 and 14, the surfaces of the 3D printed nails were 
washed with ethanol to remove excess formulation. Confocal Raman spectroscopy (CRS) was used 
to profile the drug in the 3D printed nail. At the end of the Franz cell studies, no drug was observed 
in the receptor phase. CRS studies confirmed penetration of the active into the model nails with 
reproducible depth profiles. Our ongoing work is focused on synthesising commercial and non-
commercial printable resins that can replicate the physical and chemical characteristics of the human 
nail. This will allow further evaluation of actives for ungual therapy and advance the development 
of the surrogate nail tissue model. 
Keywords: pharmaceutical analyses; transungual drug delivery; 3D printing; ciclopirox olamine; 
confocal Raman spectroscopy; drug testing surrogates 
 
1. Introduction 
The nail plate can be characterised as a thin (0.25–0.60 mm length), hard, slightly elastic, 
translucent and convex structure. Formed by approximately 25 layers of dead keratinised flattened 
cells, the nail plate is tightly bound via numerous intercellular links, membrane-coating granules and 
desmosomes [1]. An assessment of the efficacy of new formulations for treatment of nail diseases 
requires the provision of human nails or an appropriate surrogate tissue. However, human nails are 
difficult to source, variable in quality and their use is associated with ethical and safety issues [2–6]. 
The emergence of additive manufacture (AM) technologies such as 3D printing has heralded a 
new era for the design of non-expensive and efficient reproducible polymeric matrices. With printer 
specifications that can now achieve layer thicknesses of ~25 µm and allied with digital design, 3D 
desktop printers are becoming powerful tools in pharmaceutical research [7–10]. In recent years, 3D 
printing has evolved to develop bioprinting of tissues including skin, bone, cartilage and skeletal 
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muscle [11–13]. However, the costs of biocompatible resins allied with the complexities of biological 
tissues have limited the widespread use of the technology.  
In the present work, the research aimed to develop a suitable polymeric membrane that would 
simulate the permeation properties of a human nail. When conducting permeation studies with nails, 
a further problem that researchers face is the natural curvature of the nail. This means that nails are 
usually flattened, or pressure is applied to the tissue so as to assemble it in a diffusion cell and this 
may compromise nail integrity leading to microtears and misleading permeation information. A 
secondary objective of the present study was, therefore, to ensure the 3D printed nails were flat to 
ensure ease of mounting in diffusion cells. A commercial antifungal lacquer containing ciclopirox 
olamine (Mycoster 80 mg/g) was selected for in vitro studies with the 3D printed nails. 
2. Materials and Methods  
2.1. Materials 
Ciclopirox olamine, anhydrous acetic acid, sodium edetate and acetylacetone were supplied by 
Sigma Aldrich, Dorset, UK. Phosphate buffer saline (PBS) tablets were purchased from Oxoid 
Limited, Basingstoke, UK. A commercial formulation of ciclopirox olamine, Mycoster 80 mg/g (Pierre 
Fabre Dermo-Cosmetique, Paris, France), was purchased from a pharmacy retailer. High 
performance liquid chromatography (HPLC) grade water and acetonitrile were obtained from Fisher 
Scientific, Loughborough, UK. 
Nail matrices were drawn in silico using the online computer aided design (CAD) program, 
TinkerCAD (Autodesk, San Rafael, CA, USA). Graphical images of the designs were imported to 
Preform™ software (version: 2.14.0, Formlabs, Somerville, MA, USA) prior to printing. 3D printing 
was carried out using two different stereolithography (SLA) machines: Form1+ and Form2 (Formlabs, 
Somerville, MA, USA). The stereolithography resin used for printing was GPCL04 (Formlabs, 
Somerville, MA, USA). This is an acrylate-based resin and was selected because it allows preparation 
of transparent matrices to facilitate visual examination of drug uptake. 
2.2. 3D Printing Prototype (Design and Printing Parameters) 
As shown in Figure 1, the 3D printed polymeric matrix was manufactured with the following 
specifications and corresponding tolerances: outer diameter (O.D.) = 15.0 ± 1.0 mm and height (h) = 
0.50 ± 0.10 mm. Printing was carried out using a resolution of 25 µm (conferring ~ 20 unique layers 
per nail) and a resin tank temperature of 28 °C. In the process of manufacturing 3D printed materials, 
supports are required for removal of the object from the building platform at the end of the process. 
Preform™ generated supports were not selected for this study. Instead, the building plate was coated 
prior to printing with Scotch-Blue™ painter’s tape for multi-surfaces 24 mm (3M, Flemington, NJ, 
USA) to allow a rapid removal of the printed matrix, preventing the damage of both the printout nail 
and printing platform. Post-curing of resin was achieved by exposing the 3D printed matrices to UV 
light (405 nm) at 60 °C for 30 min using the Form Cure (Formlabs, Somerville, MA, USA) [14]. All 
measurements were done on different areas of the 3D printed scaffolds with an MW110-15WR 
electronic digital Vernier calipers (Bowers Group, Surrey, UK) and surveyed using Prism7 (Version 
7.05, GraphPad Software, San Diego, CA, USA). 
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Figure 1. TinkerCad desing of the 3D printed nail (left) and image of 3D printed nail printout: red 
dots signify the approximate locations that were scanned using confocal Raman spectroscopy (right).  
2.3. High Performance Liquid Chromatographic (HPLC) Analysis 
The analysis of ciclopirox olamine was carried out using an HPLC (Agilent Technologies 1200 
series) equipped with an Agilent G1322A degasser, G1311A quaternary pump, G1329A auto sampler 
and G1316A thermostat (Agilent Technologies, Santa Clara, CA, USA). The column used was a 
Phenomenex Luna CN (nitrile silica gel) column (Phenomenex, Macclesfield, UK). The length, 
internal diameter and particle size were 120 mm, 4 mm and 5 µm, respectively. To ensure desorption 
of any interfering metal ions in the stationary phase, the column was rinsed prior to use with a 
mixture of acetonitrile:water (50:50) containing acetylacetone (0.1%) and anhydrous acetic acid (0.1%) 
over 15 h and subsequently with mobile phase for 5 h at a flow rate of 0.2 mL/min. The mobile phase 
consisted of acetonitrile:water (23:77) with anhydrous acetic acid (0.1%) and sodium edetate (0.1%). 
The mobile phase was degassed using an ultrasonicator (VWR International, Lutterworth, UK) prior 
to use to remove air bubbles. The flow rate of the mobile phase was 0.7 mL/min and the column 
temperature set at 23 °C. The chromatogram was acquired at a wavelength of 298 nm. A sample 
volume of 10 µL was injected for a total run time of 25 min [15] and the drug peak eluted at 12.4 min. 
A known amount of ciclopirox olamine was dissolved in PBS (pH 7.3 ± 0.1) and a stock solution (2 
mg/mL, equivalent to 1.54 mg/mL of ciclopirox) prepared. The stock solution was diluted to prepare 
a range of concentrations of ciclopirox olamine. The calibration curve was constructed in the 
concentration range of 0.05-1.54 mg/mL of ciclopirox. A linear relationship was found between 
concentration and peak area with regression coefficient values (r2) of greater than 0.99, with a limit of 
detection (LOD) of 0.025 mg/mL and a limit of quantification (LOQ) of 0.051 mg/mL. 
2.4. Permeation Study with Commercial Formulation in 3D Printed Polymeric Matrices 
The nail printouts were placed in freshly prepared PBS (pH 7.3 ± 0.1) to hydrate for 24 h prior to 
the start of the experimental work. Permeation studies of the ciclopirox olamine lacquer formulation 
(Mycoster 80 mg/g) in glass Franz diffusion cells were conducted under finite dose (13 µL/cm2) 
conditions with a daily application to the 3D polymeric matrices for 14 days. The final nails selected 
for evaluation had a mean application area of 1.13 ± 0.05 cm2. The integrity of the polymeric matrices 
was confirmed by evaluation of electrical resistance as reported previously for topical permeation 
studies [16]. Freshly prepared PBS (pH 7.3 ± 0.1) was used as the receptor solution since this medium 
provides sink conditions for the drug. Once the 3D printed nail temperature had equilibrated to 32 ± 
1 °C, the formulation was applied using an Eppendorf Multipette Plus. Formulations were applied 
daily after washing with distilled water to remove residual formulation from the previous day’s 
application. A volume of 200 µL of receptor solution was removed from the receptor compartment 
once daily up to 14 days, with sample replacement using fresh temperature equilibrated PBS solution. 
On days 7 and 14, the 3D printed polymeric surfaces were washed using a cotton tip and distilled 
water, and a second cotton tip containing a 96% ethanolic solution as reported elsewhere [17]. All 
samples were analysed using HPLC. The number of replicate experiments was n = 4. 
2.5. Confocal Raman Spectroscopy (CRS) Study of Ciclopirox Olamine in 3D Printed Polymeric Matrices 
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CRS was performed using a Model 3510 Skin Analyser (RiverD, Rotterdam, Netherlands) with 
the fingerprint region (400–2200 cm−1) using a 785 nm laser. Spectral acquisition and analysis were 
conducted using software packages, RiverIcon V3.0 and SkinTools V2.0 D2O respectively (RiverD, 
Rotterdam, Netherlands). Each of the 3D printed nails were cut into smaller fragments and three 
pieces from each nail were used to profile the drug as shown in Figure 1. A drop of HPLC grade 
water was placed on the sample window directly above the microscope objective and a piece of 3D 
printed polymeric matrix (formulation application side facing down) was placed on the window. A 
stainless-steel weight was placed directly above the 3D printed nail to ensure good contact was 
obtained between the polymeric printout and microscope window. The piece of 3D printed matrix 
was scanned using a 20 s exposure time, acquired in 10 µm steps with measurements taken over a 
total depth of 400 µm. All measurements were taken at room temperature. Spectral data were 
analysed via Raman band ratios. The 710 cm−1 Raman band of ciclopirox was normalised by area to 
the 1446 cm−1 Raman band present in each spectrum using Prism7 (Version 7.05, GraphPad Software, 
San Diego, CA, USA).  
3. Results and Discussion 
3.1. 3D Printing Prototype (Design and Printing Parameters) 
The initial prototyped process for printing 3D nail polymeric matrices was complex since it 
involved the removal of minor structures from the printer’s building platform without breakage, 
cracking and/or deformation of the printout. Prior to printing, the inclusion of building supports that 
could assist in the removal of the printed nails was attempted but dismissed due to poor lithography 
outcomes. To achieve reproducibility of the printing methodology, the 3D printer’s building platform 
was then coated using different polymeric materials (Table 1). The Scotch-Blue™ painter’s tape for 
multi-surfaces allowed for a rapid removal of the printouts from the printing platform which 
facilitated the development of the desired nail structures. 
Table 1. Building platform coatings used during the 3D printing process. 
Platform Coating Removal of Printout from Building Platform 
Inspection of 3D 
Printed Scaffold 1 
(Mean ± SD) 
None 2 
Printout breakage and platform damage 
on attempt 
h (0.51 ± 0.02 mm) 
O.D. (-) 3 
White masking tape 50 mm (Eurocel 
Ltd., Alfreton, UK) 
Accessible removal of the printout from 
the plate. Extended peeling of the coating 
during printing 
h (0.28 ± 0.22 mm) 
O.D. (9.3 ± 5.5 mm) 
Blue masking tape HB 850 12 mm 
(Hi-Bond Tapes Ltd., Corby, UK) 
Printout did not adhere to the coating - 
Kapton tape 50 mm (3D FilaPrint, 
Essex, UK) 
Unmanageable removal of the coating 
from the plate. Hindrance to detach 
printout from coating 
h (0.48 ± 0.03 mm) 
O.D. (15.0 ± 0.01 mm) 
Scotch-Blue™ painter’s tape for 
multi-surfaces 24 mm (3M, 
Flemington, NJ, USA) 
Accessible removal of the printout from 
the plate. Simple separation of the 
printout from coating 
h (0.50 ± 0.01 mm) 
O.D. (15.0 ± 0.02 mm) 
1 Printing replicates are shown as n = 27 (Nine nails per each of three printing batches). 2 Printing done directly 
on the building plate. 3 Measurement was not attained due to breakage of the printout.  
Printing of new polymeric constructs using the abovementioned platform coating was then 
obtained in different layer resolutions: 100, 50 and 25 µm, which corresponded to a total sum of ~5, 
10 and 20 layers per scaffold respectively (Figure 2). This allowed for a more accurate replication of 
the human nail layering characteristics (~25 layers).  
Pharmaceutics 2019, 11, 250 5 of 9 
 
 
Figure 2. Illustration of the different number of layers present per scaffold using (left to 
right) 25, 50 and 100 µm printing resolutions. 
Multiple printing attempts which included the manipulation of nail dimensions (i.e., thickness 
and length), layer resolution and temperature indicated a better printing control for thicker nail 
structures with less deviation in width throughout the entire nail matrix (Table 2). Throughout these 
studies, no clear shrinkage of the printout (post-curing) was seen with deviations being attributed to 
the printing methodology. Optimal printing conditions which rendered the most desirable printout 
that closely mirrored the nail’s architecture (O.D. = 15 mm; h = 0.50 mm; printer resolution: 25 µm; 
printing temperature = 28 °C) were then used to conduct the permeation study. 
Table 2. Printing conditions (temperature and resolution) for the development of different 3D printed 
nails scaffolds (n = 18). 
3D Nail Thickness 
(mm) 






Inspection of 3D Printed 




100 h (0.50 ± 0.01 mm);  
O.D. (15.0 ± 0.1 mm) 
50 
h (0.50 ± 0.01 mm);  
O.D. (15.1 ± 0.2 mm) 
25 
h (0.50 ± 0.01 mm);  
O.D. (15.0 ± 0.2 mm) 1 
20 
100 
h (0.50 ± 0.01 mm);  
O.D. (15.1 ± 0.1 mm) 
50 
h (0.51 ± 0.01 mm);  
O.D. (15.0 ± 0.1 mm) 
25 
h (0.51 ± 0.02 mm);  




h (0.50 ± 0.01 mm);  
O.D. (20.1 ± 0.1 mm) 
50 
h (0.51 ± 0.01 mm);  
O.D. (20.3 ± 0.2 mm) 
25 
h (0.51 ± 0.02 mm);  
O.D. (20.3 ± 0.2 mm) 
20 
100 
h (0.51 ± 0.01 mm);  
O.D. (20.2 ± 0.1 mm) 
50 h (0.51 ± 0.02 mm);  
O.D. (20.3 ± 0.2 mm) 
25 
h (0.52 ± 0.02 mm);  
O.D. (20.3 ± 0.2 mm) 
0.30 15.0 28 
100 
h (0.32 ± 0.01 mm);  
O.D. (15.0 ± 0.1 mm) 
50 
h (0.32 ± 0.02 mm);  
O.D. (15.0 ± 0.1 mm) 
25 
h (0.29 ± 0.01 mm);  
O.D. (15.1 ± 0.2 mm) 




h (0.32 ± 0.02 mm);  
O.D. (15.1 ± 0.1 mm) 
50 
h (0.29 ± 0.02 mm);  
O.D. (15.1 ± 0.2 mm) 
25 
h (0.29 ± 0.02 mm);  




h (0.31 ± 0.02 mm);  
O.D. (20.1 ± 0.1 mm) 
50 
h (0.32 ± 0.01 mm);  
O.D. (20.3 ± 0.2 mm) 
25 
h (0.32 ± 0.02 mm);  
O.D. (20.3 ± 0.2 mm) 
20 
100 
h (0.33 ± 0.02 mm);  
O.D. (20.1 ± 0.2 mm) 
50 
h (0.28 ± 0.03 mm);  
O.D. (20.2 ± 0.3 mm) 
25 
h (0.28 ± 0.02 mm);  
O.D. (20.3 ± 0.2 mm) 
1 Conditions applied for the manufacture of the 3D printed “nail” scaffold used in the pharmaceutical 
formulation permeation study. 
3.2. Permeation Study with Commercial Formulation in 3D Printed Polymeric Matrices 
In vitro testing on nail tissue is limited by the small surface areas of these membranes, 
approximately 0.03–0.78 cm2, when mounted in conventional modified Franz diffusion cells [2,3,18–
20]. This new approach enabled the printing of polymeric constructs that mimic a typical human 
nail’s specifications (i.e., number of layers, thickness and diameter) but with the advantage of a wider 
area for drug application of 1 cm2. 
After the development of 3D printed nail prototype surrogates, a widely studied antifungal 
formulation was chosen to test these preliminary polymeric constructs. Permeation studies 
demonstrated that ciclopirox olamine was not detected in the receptor fluid after 14 days. Previous 
studies indicate that only small amounts of the active, ranging from 0.25–0.69% of the applied dose, 
permeated the human nail plate [17,19,20]. Due to the absence of a drug in the receptor phase, CRS 
was subsequently used to profile drug uptake in the 3D nails. 
3.3. Confocal Raman Spectroscopy (CRS) Study of Ciclopirox Olamine in 3D Printed Polymeric Matrices 
Representative spectra of ciclopirox olamine, the commercial formulation and the 3D printed 
polymeric matrix, are shown in Figure 3 with key Raman bands identified. Spectra were scaled and 
offset for clarity. The 604 cm−1 band was only identified in the 3D printed polymeric construct. This 
peak was used to confirm the position of the surface of the 3D printed nail and was also used as a 
point to align depth profiles. The 710 cm−1 band was present for both ciclopirox olamine and the 
commercial formulation. Understandably, there are many common peaks between the commercial 
formulation and ciclopirox olamine, and by comparing the two spectra, it is evident that the 710 cm−1 
peak is only produced by ciclopirox olamine and not by the formulation excipients. This peak is 
sharper in the ciclopirox olamine powder spectrum than it is in the commercial formulation because 
the drug in the formulation is in solution and not that of a pure substance. Raman spectra of 
crystalline substances are more intense when compared to those obtained in solutions. The 710 cm−1 
band was selected to detect the penetration of ciclopirox since it did not interfere with any bands 
produced from the 3D printed nail spectra. Peak areas of this band were normalised to the 1446 cm−1 
band that is attributed to CH bending [21]. The 1446 cm−1 is relatively large in both the 3D printed 
polymeric matrix and the commercial formulation. Excipients in the formulation, such as isopropyl 
alcohol, ethyl acetate and the methylvinyl ether-maleic acid monobutylester copolymer all contribute 
to this spectral feature. This peak is broader in the 3D printed polymeric matrix and there is a distinct 
lack of sharp peaks is the spectrum, suggesting that the polymer chains matrix have a random 
arrangement. 
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Figure 3. Reference spectra for Ciclopirox olamine, Mycoster® and 3D printed nail.  
As shown in Figure 4, ciclopirox content was detected in the residual dried formulation film. 
CRS measurements also confirmed the mean residual lacquer film thickness as 112.5 ± 45.6 µm. The 
first frame measured inside the 3D printed nail was taken at 0 µm (Figure 4) and subsequently, deeper 
measurements were expressed with positive depth values. Depth profiles between replicates were 
consistent as shown in Figure 4A,B. 
 
Figure 4. (A) Ciclopirox depth profiles in each of the 3D printed nails (n = 4) from 3 scans (mean ± 
SD); (B) average ciclopirox depth profile for all 4 nail replicates (mean ± SD). 
Irrespective of the formulation residual film thickness, the concentration of the dried Mycoster 
80 mg/g lacquer was the same for each of the 3D printed polymeric matrices (1040 ± 57 µg). A total 
of 423 ± 36 µg of ciclopirox was found in the residual dried formulation layer after CRS measurements 
were conducted. The ciclopirox olamine depth profile shown in Figure 4A has a flat portion from -
200 µm to 0 µm for each of the experimental replicates. This is because the ciclopirox olamine 
concentration in the dried lacquer is uniform throughout the depth of this formulation film. The 
Raman band ratio for ciclopirox olamine in the dried formulation film is constant until scans are 
acquired from the 3D printed matrix. Scans taken from 0 µm to 25 µm shown a rapid reduction in 
the ciclopirox olamine concentration. This is because the drug is diffusing from what is effectively a 
reservoir of drug in the dried film into the 3D printed matrix (i.e., a high drug concentration 
movement into the polymeric matrix that has a drug concentration of zero). From approximately 25 
µm to 100 µm, the depth profile becomes shallower and shows ciclopirox olamine is accumulating in 
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of ciclopirox olamine below 200 µm from the surface of the polymeric matrix. The relatively flat 
portion of the depth profile from 150 µm to 200 µm confirms that there is no ciclopirox olamine at 
this depth and explains why ciclopirox olamine was not detected in the receptor fluid during the 
permeation experiments. It is clear from Figure 4A that the 3D printed nail is a highly reproducible 
material as each replicate matrix produces a depth profile that is comparable in shape. 
4. Conclusions 
The use of polymeric matrices that not only mimic chemical, but also physical and anatomical 
properties of the human nail would address the problems researchers face when sourcing such 
tissues for research and drug development. This study confirms reproducible nail penetration 
profiles for the model actively studied. Necessary fine-tuning of printing parameters allied with the 
synthesis of new polymeric resins will allow for more control of the composition and porosity of the 
nail scaffold going forward. 
Current and future work is focused on modifying commercial resins and synthesising novel 
polymers that incorporate the specific chemistry of the human nail namely, disulfide bonds. 
Furthermore, it is hoped that modification and diversification of our current 3D printing 
methodology can achieve different levels of polymer porosity that can translate into diseased nail 
models. However, the existing experimental model in this study requires vast lengths of time (4–5 
weeks) to allow for both 3D printed constructs and single molecular permeation profiles to be 
characterised and evaluated. Still, we are currently examining the permeation properties of other 
pharmaceutical ingredients used in ungual preparations with accompanied permeation study 
methodology updating to accommodate these 3D models. 
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